Heska Corp (HSKA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

3760 ROCKY MOUNTAIN AVENUE LOVELAND, CO 80538

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. It operates in two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals and fish. In February 2013, it announced the acquisition of 54.6% interest of Cuattro Veterinary USA, LLC.

Data as of 2020-08-01
Market Cap903.691 Million Shares Outstanding9.392 Million Avg 30-day Volume68.077 Thousand
P/E Ratio Dividend Yield EPS-1
Price/Sales9.447 Price cash flow ratio159.9 Price free cash flow ratio-89.4
Book Value28.82 Price to Tangible Book4.09 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.268781
BETA1.66725 52-week High/Low110.9 / 50.0 Stddev0.138363
View SEC Filings from HSKA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 1 (0.07%)
13F Filers holding this stock: 119 27 (1.77%)
Aggregate 13F shares on 03/31/2020: 7.459 Million 3.318 Million
Aggregate 13F shares on 12/31/2019: 7.804 Million 3.441 Million
Percent change: -4.42% -3.59%
Funds creating new positions: 13 5
Funds Adding to an existing position: 43 11
Funds closing out their position: 20 5
Funds reducing their position: 43 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HSKA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HSKA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9.2 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WILSON KEVIN S. CEO AND PRESIDENT

  • Officer
  • Director
398,011 2020-08-05 5

FURLONG MARK F

  • Director
49,422 2020-06-05 1

GRASSMAN CATHERINE EVP, CFO

  • Officer
3,723 2020-06-01 3

WISNEWSKI NANCY CHIEF OPERATING OFFICER

  • Officer
0 2020-04-16 2

EYL STEVEN M. EVP, CCO & PRES.SCIL

  • Officer
0 2020-04-16 2

SVEEN CHRISTOPHER D. CAO & GENERAL COUNSEL

  • Officer
14 2020-04-16 2

BAKER ELEANOR F. EVP, MANAGING DIRECTOR &

  • Officer
190 2020-04-16 2

LARSON SHARON J.

  • Director
6,839 2020-04-08 1

SVEEN DAVID E.

  • Director
32,741 2020-04-08 1

TROWBRIDGE BONNIE J.

  • Director
4,089 2020-04-08 1

HUMPHREY SCOTT

  • Director
5,112 2020-04-08 1

NAPOLITANO JASON A CHIEF STRATEGY OFFICER

  • Officer
62,799 2019-12-30 3

GORDON G IRWIN

  • Director
25,074 2018-11-29 0

MCMAHON JOHN CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-10-29 0

LIPPINCOTT ROD EVP, COMP. ANIMAL HEALTH SALES

  • Officer
8,573 2018-08-31 0

ASAKOWICZ STEVE EVP, COMP. ANIMAL HEALTH SALES

  • Officer
8,400 2018-08-27 0

AROESTY JASON D EVP, INTERNATIONAL DIAGNOSTICS

  • Officer
0 2018-07-25 0

WRENN CAROL

  • Director
5,249 2018-05-03 0

MCGINLEY MICHAEL J PRESI, BIOLOGIC. & PHARM.

  • Officer
86,776 2018-03-17 0

GRIEVE ROBERT B EXECUTIVE CHAIR

  • Officer
  • Director
106,331 2015-08-28 0

AYLESWORTH WILLIAM A

  • Director
37,397 2015-03-09 0

SASEN JOHN F E.V.P. & CHIEF MKT. OFFICER

  • Officer
No longer subject to file 2013-02-22 0

BENT MICHAEL A V.P.ACTG. OFFICER & CONTROLLER

  • Officer
9,773 2012-12-28 0

ZACHARA CLAUDINE

  • VP, MARKETING
0 2012-12-19 0

APERFINE JOSEPH EVP, SALES AND MARKETING

  • Officer
0 2012-12-19 0

CMC MASTER FUND, L.P.

CMC MASTER FUND PARTNERS, LLC

  • 10% Owner
No longer subject to file 2012-10-09 0

EIO PETER

  • Director
0 2012-05-08 0

MCCORMICK LOUISE L.

  • Director
0 2012-05-08 0

CMC MASTER FUND, L.P.

CMC MASTER FUND PARTNERS, LLC

C.M. CAPITAL ADVISORS, LLC

C.M. CAPITAL CORP

  • 10% Owner
579,045 2012-02-15 0

SNODGRASS GERALD L VP, SALES

  • Officer
0 2009-11-10 0

PACIFIC COAST INVESTORS LTD

  • 10% Owner
No longer subject to file 2009-08-25 0

FLANDERS JOHN R V.P., GENERAL COUNSEL

  • Officer
32,500 2008-11-25 0

CHARTER VENTURES II, L.P.

CHARTER VENTURES

  • 10% Owner
No longer subject to file 2008-06-20 0

RITTER JOSEPH H EVP, GLOBAL BUS. OPERATIONS

  • Officer
0 2007-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by daughter

2020-08-05 S 2,144 $107.00 d 4,288 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son ii

2020-08-05 S 100 $109.00 d 4,188 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son

2020-08-05 S 2,144 $107.00 d 4,286 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son iii

2020-08-05 S 200 $109.00 d 4,088 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son ii

2020-08-05 S 2,144 $107.00 d 4,288 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by daughter

2020-08-05 S 100 $109.00 d 4,188 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son iii

2020-08-05 S 2,144 $107.00 d 4,288 398,011.00 indirect yes

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT by son

2020-08-05 S 200 $109.00 d 4,086 398,011.00 indirect yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments